Many people will struggle to pay for heating over the colder months
A campaign group is calling on Nottingham City Council to refrain from potentially bringing the axe down on three of its libraries so they can be used as "warm havens" this winter. Despite new Prime Minister Liz Truss revealing plans to cap energy bills at £2,500, many households will still struggle over the winter months, with bills having risen from £1,277 just a year ago.
In Nottingham, however, there are some issues. The central library in Angel Row has been closed for more than two years, with its replacement not expected to open until the Summer of 2023, and as part of the Labour council's progress towards financial stability, three of its libraries may still be closed.
The city council recently detailed five options to save the Basford, Aspley and Radford-Lenton libraries from closure, but concerns were then raised after councillors argued the authority was providing a network of libraries which meet the needs of the city's citizens, at a time when one is yet to open and three remain under threat.
The Libraries Connected charity, which represents, supports and promotes public libraries, has also published a report which states vulnerable people have been using libraries more regularly as a way to stay warm. Chief executive Isobel Hunter added: “Public libraries have always offered a warm safe space to those who need it, but the energy crisis means demand is likely to be much higher over the colder months.
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia | Journal of Clinical OncologyPURPOSE The FMS-related tyrosine kinase 3 (FLT3) inhibitor gilteritinib is standard therapy for relapsed/refractory FLT3-mutated (FLT3mut) acute myeloid leukemia (AML) but seldom reduces FLT3mut burden or induces sustained efficacy. Gilteritinib combines synergistically with the BCL-2 inhibitor venetoclax in preclinical models of FLT3mut AML. METHODS This phase Ib open-label, dose-escalation/dose-expansion study (ClinicalTrials.gov identifier: NCT03625505) enrolled patients with FLT3 wild-type and FLT3mut (escalation) or FLT3mut (expansion) relapsed/refractory AML. Patients received 400 mg oral venetoclax once daily and 80 mg or 120 mg oral gilteritinib once daily. The primary objectives were safety, identification of the recommended phase II dose, and the modified composite complete response (mCRc) rate (complete response [CR] + CR with incomplete blood count recovery + CR with incomplete platelet recovery + morphologic leukemia-free state) using ADMIRAL phase III–defined response criteria. RESULTS Sixty-one patients were enrolled (n=56 FLT3mut); 64% (n=36 of 56) of FLT3mut patients had received prior FLT3 inhibitor therapy. The recommended phase II dose was 400 mg venetoclax once daily and 120 mg gilteritinib once daily. The most common grade 3/4 adverse events were cytopenias (n=49; 80%). Adverse events prompted venetoclax and gilteritinib dose interruptions in 51% and 48%, respectively. The mCRc rate for FLT3mut patients was 75% (CR, 18%; CR with incomplete blood count recovery, 4%; CR with incomplete platelet recovery, 18%; and morphologic leukemia-free state, 36%) and was similar among patients with or without prior FLT3 inhibitor therapy (80% v 67%, respectively). The median follow-up was 17.5 months. The median time to response was 0.9 months, and the median remission duration was 4.9 months (95% CI, 3.4 to 6.6). FLT3 molecular response (| 10−2) was achieved in 60% of evaluable mCRc patients (n=15 of 25). The median overall survival for FLT3mut patients was
Read more »
COVID-19 risk substantially reduced in seniors who receive 4th mRNA boosterIn a recent study published in the Annals of Internal Medicine, researchers in Singapore estimated the effectiveness of the second booster (fourth dose) vaccination with messenger ribonucleic acid (mRNA) vaccines against symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections with the SARS-CoV-2 Omicron variant and associated hospitalizations with among individuals aged ≥80 years.
Read more »
We've won fight to install double headstone after 'racist' council banned themA GYPSY family have won their battle with council chiefs after being banned from installing a double headstone. David Loveridge, 80, said he “will sleep tonight” knowing he can now…
Read more »
Call for city's under-threat libraries to be used as 'warm havens''Research shows that over 80% of library leaders expect an increase in people using libraries to keep warm'
Read more »